Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04155710 · ClinicalTrials.gov registry record · Phase 1
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL
A Phase 1 study, sponsored by Iovance Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT04155710: Completed Phase 1 study, sponsored by Iovance Biotherapeutics.
NCT04155710 is a Phase 1 study that has completed, run by Iovance Biotherapeutics. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04155710, a Phase 1 study, has completed, sponsored by Iovance Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a Phase 1/2, study evaluating IOV-2001 (Adoptive Cell Therapy) composed of autologous PBL (Peripheral Blood Lymphocytes) in patients with CLL/SLL, which has relapsed or is relapsing during treatment with ibrutinib or acalabrutinib.
Primary Outcome
to determine the recommended Phase 2 dose of IOV-2001 followed by interleukin-2 (IL-2)
Interventions
- DRUG IL-2
- BIOLOGICAL IOV-2001
- DRUG Low dose IL-2
- DRUG High dose IL-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2020-02-19 |
| Est. Completion | 2024-12-02 |
| Phase | Phase 1 |
What the finished NCT04155710 record still lists
NCT04155710 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 4 interventions - of which IL-2 is the first listed.
NCT04155710 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04155710 about?
NCT04155710 is a clinical study titled "Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL". This is a Phase 1/2, study evaluating IOV-2001 (Adoptive Cell Therapy) composed of autologous PBL (Peripheral Blood Lymphocytes) in patients with CLL/SLL, which has relapsed or is relapsing during treatment with ibrutinib or acalabrutinib.
What is the current status of trial NCT04155710?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2020-02-19. Estimated completion is 2024-12-02.
What interventions are being tested in trial NCT04155710?
The interventions under investigation include: IL-2 (DRUG), IOV-2001 (BIOLOGICAL), Low dose IL-2 (DRUG), High dose IL-2 (DRUG).
Who is sponsoring clinical trial NCT04155710?
This trial is sponsored by Iovance Biotherapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04155710's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI